about
Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling.Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.Minimizing DILI risk in drug discovery - A screening tool for drug candidates.Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.Simultaneous Assessment of Clearance, Metabolism, Induction and Drug-Drug Interaction Potential using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor.In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.The In Vitro Biotransformation of the Fusion Protein Tetranectin-Apolipoprotein A1The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic ModellingCharacterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver MicrosomesApplication of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico ToolsCoexpression of Human Hepatic Uridine Diphosphate Glucuronosyltransferase Proteins: Implications for Ontogenetic Mechanisms and Isoform CoregulationMicrophysiological systems for ADME-related applications: current status and recommendations for system development and characterizationImpact of Intracellular Concentrations on Metabolic Drug-Drug Interaction StudiesOptimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry
P50
Q31152600-26444750-694B-45D5-873F-D9B4DE211BCBQ38928302-E02829ED-AF5F-4294-AC13-9088796AEF98Q42820442-55C36C8A-0E4D-4F23-A599-636B1003B5E1Q47333263-800108E4-1574-4F91-9F5E-8C6E219A62F0Q48036786-92A9C87A-9260-4598-9CEA-FA2276795997Q49914986-8F60E59C-32FC-45D1-B324-EFD220FCBE33Q53191682-D42CECFE-6113-4F44-AADB-2C7A8EA8FA27Q64109965-B015A839-1E9E-42BC-B84D-1316D8E134A0Q88968527-EAB5BAF5-7620-4F4C-9286-2983200EE8C5Q90014315-36577AF4-0EBB-4748-BF75-B4F8C5F68619Q92008189-45FE79A0-1AE5-4D02-84B9-CF30836D1AD7Q92269929-0AFF2786-1F5E-4F5D-B767-52B8355C482EQ92611401-6FE4E784-49F2-4754-A646-7CDBD45236B3Q92866081-DE0FBF7C-4238-47A3-843F-DF84E1259EF7Q93380696-D0F220FA-3C83-439A-94DE-FD6FDB0C7C0F
P50
description
researcher (ORCID 0000-0001-7331-3559)
@en
wetenschapper
@nl
name
Stephen Fowler
@en
Stephen Fowler
@nl
type
label
Stephen Fowler
@en
Stephen Fowler
@nl
prefLabel
Stephen Fowler
@en
Stephen Fowler
@nl
P31
P496
0000-0001-7331-3559